SCHEMBL30765660

SCHEMBL30765660

CC(C)(C)OC(=O)Cn1c(-c2ccccc2)ncc(Br)c1=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ELANE P08246 8/20 0.40
F2 P00734 1/20 0.40
CMA1 P23946 1/20 0.39
CTRC Q99895 1/20 0.39
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
JAK3 P52333 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.37
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765438 0.86 KDM4E (0.50) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6087779 0.86 CTRC (0.52) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL30765666 0.86 KDM4E (0.51) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL30765904 0.84 KDM4E (0.47) KDM4EALDH1A1GAAELANEF2
SCHEMBL31558583 0.82 KDM4E (0.51) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL7476393 0.82 ALDH1A1 (0.47) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL30765447 0.81 L3MBTL1 (0.65) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6245424 0.80 ELANE (0.49) KDM4EALDH1A1ELANEMAPTSMN1; SMN2
SCHEMBL23460649 0.79 ELANE (0.47) KDM4EALDH1A1ELANEF2CMA1
SCHEMBL6178282 0.79 ELANE (0.51) KDM4EALDH1A1ELANEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed